Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Pediococcus acidilactici CECT9879 (pA1c) Counteracts the Effect of a High-Glucose Exposure in C. elegans by Affecting the Insulin Signaling Pathway (IIS)

  • 2022-02-28
  • International Journal of Molecular Sciences 23(5)
    • Deyan Yavorov-Dayliev
    • F. Milagro
    • J. Ayo
    • M. Oneca
    • P. Aranaz

Abstract

The increasing prevalence of metabolic syndrome-related diseases, including type-2 diabetes and obesity, makes it urgent to develop new alternative therapies, such as probiotics. In this study, we have used Caenorhabditis elegans under a high-glucose condition as a model to examine the potential probiotic activities of Pediococcusacidilactici CECT9879 (pA1c). The supplementation with pA1c reduced C. elegans fat accumulation in a nematode growth medium (NGM) and in a high-glucose (10 mM) NGM medium. Moreover, treatment with pA1c counteracted the effect of the high glucose by reducing reactive oxygen species by 20%, retarding the aging process and extending the nematode median survival (>2 days in comparison with untreated control worms). Gene expression analyses demonstrated that the probiotic metabolic syndrome-alleviating activities were mediated by modulation of the insulin/IGF-1 signaling pathway (IIS) through the reversion of the glucose-nuclear-localization of daf-16 and the overexpression of ins-6 and daf-16 mediators, increased expression of fatty acid (FA) peroxisomal β-oxidation genes, and downregulation of FA biosynthesis key genes. Taken together, our data suggest that pA1c could be considered a potential probiotic strain for the prevention of the metabolic syndrome-related disturbances and highlight the use of C. elegans as an appropriate in vivo model for the study of the mechanisms underlying these diseases.

Keywords: Caenorhabditis elegans; daf-16; diabetes; insulin-signaling-pathway; obesity; probiotic; β-oxidation.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Pediococcus acidilacticiDelayed Skin AgingBeneficial
Moderate
Pediococcus acidilacticiIncreased Survival TimeBeneficial
Moderate
Pediococcus acidilacticiReduced Hepatic Fat AccumulationBeneficial
Moderate
Pediococcus acidilacticiReduced Intracellular Reactive Oxygen Species LevelsBeneficial
Small
Pediococcus acidilactici KABP™-021Delayed Skin AgingBeneficial
Moderate
Pediococcus acidilactici KABP™-021Improved Insulin SensitivityBeneficial
Large
Pediococcus acidilactici KABP™-021Increased Fatty Acid OxidationBeneficial
Moderate
Pediococcus acidilactici KABP™-021Increased Survival TimeBeneficial
Moderate
Pediococcus acidilactici KABP™-021Reduced Fatty Acid SynthesisBeneficial
Moderate
Pediococcus acidilactici KABP™-021Reduced Hepatic Fat AccumulationBeneficial
Moderate
Pediococcus acidilactici KABP™-021Reduced Intracellular Reactive Oxygen Species LevelsBeneficial
Small
Pediococcus acidilactici MAK92P26ADelayed Skin AgingBeneficial
Moderate
Pediococcus acidilactici MAK92P26AImproved Insulin SensitivityBeneficial
Large
Pediococcus acidilactici MAK92P26AIncreased Survival TimeBeneficial
Moderate
Pediococcus acidilactici MAK92P26AReduced Hepatic Fat AccumulationBeneficial
Moderate
Pediococcus acidilactici MAK92P26AReduced Intracellular Reactive Oxygen Species LevelsBeneficial
Small
Pediococcus acidilactici VPro29Improved Fatty Acid OxidationBeneficial
Moderate
Pediococcus acidilactici VPro29Improved Insulin SensitivityBeneficial
Large
Pediococcus acidilactici VPro29Increased Survival TimeBeneficial
Moderate
Pediococcus acidilactici VPro29Reduced Hepatic Fat AccumulationBeneficial
Moderate
Pediococcus acidilactici VPro29Reduced Intracellular Reactive Oxygen Species LevelsBeneficial
Small
Back to top